Oxford BioDynamics partners with Goodbody Clinic to enhance prostate cancer screening across UK

Oxford BioDynamics Plc, a leader in developing precision medicine tests, has partnered with Goodbody Clinic, a major provider of private health testing services in the UK, to offer the innovative EpiSwitch Prostate Screening (PSE) blood test. This collaboration aims to enhance the accuracy and accessibility of prostate cancer screening using the cutting-edge EpiSwitch 3D genomics platform.

Improving Diagnostic Accuracy with EpiSwitch PSE Test

The EpiSwitch PSE test, launched in the UK and US in September 2023, represents a significant advancement in prostate cancer diagnostics, boosting the predictive accuracy of standard Prostate-Specific Antigen (PSA) tests from 55% to an impressive 94%. This test not only provides a more reliable diagnostic tool but also offers high specificity and sensitivity, crucial for effective cancer detection and management.

Expanding Access Through Nationwide Clinics and Mobile Services

Goodbody Clinic, with its extensive network of over 140 clinics across the UK, will now provide the EpiSwitch PSE test at all its locations. Men can easily request the test through the Goodbody Clinic website, where they can also pay for their test and book an appointment. For added convenience, Goodbody Clinic offers a mobile phlebotomist service, allowing men to have blood samples taken at their location of choice across the UK, from Scotland to Cornwall.

Comments from Leadership

George Thomas, Chief Executive Officer of Goodbody Clinic, emphasized the benefits of the new test, stating, “The rapid EpiSwitch PSE test can significantly enhance the accuracy of detecting prostate cancer, allowing us to provide better care and peace of mind to men throughout the country. We are always looking to advance our commitment to accessible, high-quality healthcare by combining the latest innovations like the PSE with access to Goodbody’s convenient clinics and home testing solutions.”

Thomas Guiel, Chief Operating Officer of Oxford BioDynamics, also commented on the partnership: “This agreement presents an important new point of patient access for the EpiSwitch PSE test, allowing us to further extend the availability and reach of our highly accurate prostate cancer test.”

This strategic alliance between Oxford BioDynamics and Goodbody Clinic is a milestone in the field of prostate cancer screening. By integrating advanced genomic technologies with widespread clinical services, the partnership not only makes cutting-edge medical testing more accessible but also sets a new standard in the early detection and management of prostate cancer.